Clinical Trials Browser

Phase 2 × Imiquimod × Other hematologic neoplasm × Clear all

NCT02802943 2022-11-28

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell